Australasian Diabetes Advancements and Technologies Summit 2019

 


ADATS 2019 Speakers

Professor Greg Johnson
Session: Keynote Address
Title: Funding of diabetes technology in Australia – where are we at and where are we going?
Time: 0840-0905

Renza Scibilia
Session: Session 1 The Impacts Of New Therapeutics And Technology
Title: What are the ‘Benefits, Burdens and Barriers’ of new therapeutics and technology for people living with diabetes – Patient Perspective
Time: 0905-0920
BIO:
Renza Scibilia has lived with type 1 diabetes since 1998. She is a well-known advocate and peer leader, promoting a person-centred approach to healthcare, and in the development of diabetes information and technologies.
Renza is the National Program Manager for Type 1 Diabetes and Consumer Voice at Diabetes Australia. Prior to taking up this appointment, she was the Consumer Engagement Manager at Diabetes Victoria for 14 years.
Renza is well-known in the diabetes online community. She co-founded the #OzDOC community for Australians with diabetes and is well-versed in social media, its influence on people with chronic health conditions and application in peer support.
Renza is the author of one of Australia’s most widely-read patient blogs, Diabetogenic, (www.diabetogenic.wordpress.com) and has written for many publications including Mamamia and Diabetes Living Magazine.

ABSTRACT:
In 2019, people living with diabetes have a plethora of choice when it comes to finding the right technology to help manage living with the condition. But with the obvious positives technology offers, there are negatives too. Renza Scibilia has lived with type 1 diabetes for 21 years and she will speak about the double-edged sword of diabetes technology and how she has continues to search for the perfect balance between benefit and burden of diabetes tech.

Professor Jane Speight
Session: Session 1 The Impacts Of New Therapeutics And Technology
Title: What are the ‘Benefits, Burdens and Barriers’ of new therapeutics and technology for people living with diabetes – Psychologists Perspective
Time: 0920-0935

Dr. Konrad Kangru
Session: Session 1 The Impacts Of New Therapeutics And Technology
Title: What are the ‘Benefits, Burdens and Barriers’ of new therapeutics and technology for people living with diabetes – GP’s Perspective
Time: 0935-0950
ABSTRACT:
While there is no doubt that emerging technologies in Diabetes care have changed our management of this condition, access to the latest and greatest advances has not been available to all. Dr Konrad Kangru, a rural General Practitioner from north Qld, shares his insights into how many individual, institutional and systemic factors which remain barriers to greater technological uptake.

Professor Jonathon Shaw
Session: Session 2 Current Technology And Future Direction
Title: What’s new in therapeutics for diabetes now and what’s coming?
Time: 1020-1050
ABSTRACT:
Major advances are being made in therapeutics for diabetes. The most important advances currently in type 2 diabetes are the increasing recognition of the benefits of SGLT2i and GLP1 analogues on cardiac and renal outcomes. This now extends to populations without diabetes. New drugs, combining different gastrointestinal hormones are also showing significant promise for both weight loss and glycaemic control in type 2 diabetes.
In type 1 diabetes, there is also interest in non-insulin therapeutics. Several agents have been examined for their impact on both glycaemia and markers of cardiovascular risk, but uncertainty remains about their ultimate role.

Dr. Sybil McAuley
Session: Session 2 Current Technology And Future Direction
Title: What’s new in therapeutics for diabetes now and what’s coming?
Time: 1050-1120
BIO:
Dr Sybil McAuley is an Endocrinologist at St Vincent’s Hospital Melbourne and Senior Research Fellow at the University of Melbourne. In 2017, Sybil completed a PhD investigating type 1 diabetes technology and exercise. Findings from Sybil’s research have been incorporated into diabetes clinical practice guidelines for insulin pumps and for diabetes management around exercise. Supported by a five-year international JDRF research award, Sybil is now enthusiastically investigating the advancement of automated insulin delivery for people living with type 1 diabetes, with the goal of optimising glucose control while minimising the burden of diabetes self-care

David Burren
Session: Session 2 Current Technology And Future Direction
Title: Automated Insulin Delivery and Open Source
Time: 1120-1135
BIO:
David has been living with T1D for 37 years. His professional background has included engineer, nature photographer, a university lecturer. Today it also includes medical research and PWD advocate.

ABSTRACT:
Closed-loop, DIY, personalised, or “bespoke” AID systems.
The ways in which the community-driven systems have been continuing to develop, and how they’re contributing to the advances for everyone with Type 1.

Dr. Kevin Lee
Session: Session 2 Current Technology And Future Direction
Title: Decision support tools for diabetes – what’s out there and what can we learn from other health conditions?
Time: 1135-1150
BIO:
Dr Kevin Lee is an Australian trained Specialist Physician in Endocrinology/Diabetes and Nuclear Medicine.
Dr Lee consults in private practice endocrinology and diabetes. He has a special interest in both type 1 and type 2 diabetes, also interest in the diabetes technology space.
He is a staff specialist at the Royal Brisbane Women’s Hospital in Department of Nuclear Medicine and Specialised PET services and locums for private radiology clinics regularly.
Dr Lee underwent undergraduate medical training in Sydney, completing post-graduate training throughout Queensland.
He has a Masters of Health Studies in Clinical Epidemiology and is a Fellow of the Royal Australasian College of Physicians. He is an associate senior clinical lecturer with University of Queensland and a registrar supervisor with the College.
He is an advocate for patient-centric care. His other specialist interests are in osteoporosis, cardiometabolic disorders, obesity, thyroid and lipidology. He has given talks internationally and nationally in topics of endocrinology and molecular imaging.
Dr Lee is also a regular microblogger with more than 4000 followers on Twitter and more than 1000 followers on Facebook.

ABSTRACT:
Decision support tools are increasingly utilised in the health space, both for healthcare professionals but rapidly evolving with the realms of the consumers. Decision support tools in diabetes but also other health conditions will be outlined, benefits and challenges discussed.

Shaira Baptista
Session: Session 2 Current Technology And Future Direction
Title: What do adults with type 2 diabetes want from the ‘perfect’ app?
Time: 1150-1205
BIO:
Shaira Baptista is a Graduate Researcher at the University of Melbourne’s School of Population and Global Health and the Australian Centre for Behavioural Research in Diabetes. She has a background in Health Psychology, Public Health and Human-Computer Interaction. Using a mixed-methods approach, her work focusses on understanding user experiences of and engagement with diabetes self-management apps. She is also investigating the use of embodied conversational agents to deliver diabetes self-management support via apps. Her research is supported by a National Health and Medical Research Council postgraduate scholarship and a scholarship from Diabetes Australia.

ABSTRACT:
Smartphone applications offer tremendous potential to support self-management of people with type 2 diabetes. Systematic reviews and meta-analysis have found such apps can be efficacious in controlled trial settings. However, efficacy does not translate into real-world effectiveness because of limited generalisability and low uptake. We investigated the priorities and preferences of people with type 2 diabetes regarding the “perfect’ self-management app by analysing free-text responses from the second Australian Diabetes Management and Impact for Long-term Empowerment and Success study to the open-ended question “If you were describing the perfect app to help you manage your diabetes, what would it do?”

Dr. Joel Lasschuit
Session: Lunchtime Symposium
Title: Implementing Collection of HRFS Minimum Data into our Clinics
Time: 1225-1300
BIO:
Dr Joel Lasschuit is an Endocrinologist who is determined to improve outcomes for people with diabetes-related foot complications. He is a Staff Specialist in the Department of Endocrinology at St Vincent’s Hospital Sydney where he co-leads the High-Risk Foot Service (HRFS). Joel was recently appointed as the HRFS Database Manager (National Association of Diabetes Centres). In this role, he will oversee the implementation of minimum data collection in interested services across Australia. He is also involved in the HRFS Accreditation program. Joel is currently undertaking a PhD at the Garvan Institute of Medical Research, which includes a novel randomised clinical trial for patients with acute Charcot foot across nine public teaching hospitals. He has presented his research at national and international meetings. Joel recently co-founded the Sydney Diabetic Foot Interest Group (SyD FIG), an inter-institutional and inter-disciplinary case-based meeting held quarterly.

ABSTRACT:
Data collection is key to determine process and patient outcomes so as to support service quality review and improvement. Standardising data collection across High-Risk Foot Services (HRFS) nationally will create an unprecedented opportunity for audit, benchmarking and collaborative research. Several services have identified challenges in meeting Standard 8 (Quality Improvement) of the NADC Collaborative Interdisciplinary Diabetes HRFS Standards and this database is designed to help realise that Standard.

This minimum dataset has been carefully and developed into a user-friendly, accessible and free e-data collection tool by use of REDCap(TM). With the uptake of this tool across Australia, we will be creating a database of international standing. Furthermore, individual services will have the means to evaluate service efficacy and resource allocation, and to direct service improvement.

Bruce Passingham
Session: Industry Workshops
Title: AGP Guidelines and the International Consensus on Time in Range
Time: 1305-1335

Lara Pack
Session: Industry Workshops
Title: A New Way To Deliver Insulin
Time: 1335-1405
ABSTRACT:
Lessons learned from previous technologies, evolution of pump therapy, diabetes burn-out and outcome measures.

David Sutton
Session: Industry Workshops
Title: Pressure Offloading Technology
Time: 1405-1410
BIO:
Advanced pressure mapping is a business supporting other business in the allied health sector with technology to measure pressure in-shoe and the training needed to achieve the evidenced based outcomes as pre the NADC-HRFS standards and the DFA Guidelines 2018

ABSTRACT:
Objective pressure mapping. The NADC-HRFS standards, IWGDF guidelines 2019 and the DFA Guidelines 2018 ask us to off-load plantar pressure, to target a PP of 200kPa. So how do we measure it objectively to achieve an evidenced based outcome?

A/Prof John Furler
Session: Session 3 Technologies To Prevent And Manage Diabetes Complications
Title: CGM in type 2 diabetes – GP Osmotic study outcomes
Time: 1420-1445
ABSTRACT:
The GP-OSMOTIC trial tested the effect of a wearable glucose monitor in people with Type 2 diabetes. The study was set in General Practice, where most people with type 2 diabetes receive their medical care. Participants wore the monitor every three months and then discussed the results with their GP. Wearing the monitor was associated with improved glucose levels in the first six months, although this was not sustained at one year.

Dr. Joe Dawson
Session: Session 3 Technologies To Prevent And Manage Diabetes Complications
Title: Preventing amputations through technology
Time: 1445-1510
BIO:
Joe is an academic vascular, endovascular & trauma surgeon at the Royal Adelaide Hospital and Senior Lecturer at the University of Adelaide. He completed his research doctorate and surgical training in London and settled in Australia following a vascular fellowship in Adelaide. His practice includes the management of a large number of patients with advanced diabetic foot complications. His research interests include innovative technologies and he was a member of the writing committee for the recently published Global Vascular Guidelines on chronic limb-threatening ischaemia.

A/Prof Peter van Wijngaarden
Session: Session 3 Technologies To Prevent And Manage Diabetes Complications
Title: Technology, diabetes and the eye
Time: 1510-1535
BIO:
Associate Professor Peter van Wijngaarden MBBS, PhD, FRANZCO
Peter van Wijngaarden is a Principal Investigator at the Centre for Eye Research Australia (CERA) and an Associate Professor of Ophthalmology at the University of Melbourne Department of Surgery. He is a Deputy Director of CERA and an ophthalmologist in the medical retina clinic at the Royal Victorian Eye and Ear Hospital.

Peter completed his PhD in the field of retinal vascular biology at Flinders University and his post-doctoral fellowship in regeneration of the central nervous system in multiple sclerosis, at the University of Cambridge, UK. Peter’s research is focused on novel imaging technologies to detect early markers of eye and central nervous system diseases. He is clinical director and steering committee member of KeepSight, a national program to increase diabetic retinopathy screening in Australia. He is a member of the Royal Australian and New Zealand College of Ophthalmologists Future of Ophthalmology Taskforce that seeks to inform Fellows on emerging technologies in eye health. He is a member of the board and the research advisory committee of the Ophthalmic Research Institute of Australia and the medical and research committees of the Macular Disease Foundation of Australia.

ABSTRACT:
Major advances in retinal imaging technologies, in conjunction with improved treatments, have the potential to transform the eye health of people living with diabetes. Innovations in retinal imaging devices mean that self-monitoring of retinopathy (the “retinal selfie”) may soon be a reality. In parallel, the rapid rise of artificial intelligence applications for the autonomous detection of diabetic retinopathy mean that specialist-level screening may be available in the primary care setting, or even in the home, in the near future. These improvements in convenience and cost have the potential to enhance access to eye care, however digital health care systems are needed to integrate eye health in the context of comprehensive diabetes care for the best outcomes.

This presentation will address major advances in each of these areas and will cast an eye to the future of eye care for people with diabetes.

Sonia Middleton
Session: Session 4 Quick Bytes: Innovation In Diabetes Centres Using Technology
Title: Integrating artificial intelligence tools into education and practice
Time: 1600-1610
BIO:
Sonia has been the head of the Allied Health and Education Service at the Baker Heart and Diabetes Institute for the past 4 years. She currently oversees all diabetes education, dietetics and exercise physiology services, along with health professional training programs and student placements.
An Advanced Accredited Practising Dietitian Sonia has extensive experience in diabetes management, including the use of new technologies. Sonia is currently one of the project managers for the national FlexIT Insulin Health Professional Accreditation Program. Her work also includes clinical education but also some research including involvement in closed loop insulin pump studies and weight management trials.

ABSTRACT:
the Australian market to include Baker education material and resources.

Our presentation will provide an overview on what this app is and how it works. Also the outcoming pilot at Baker and plans to launch to the wider market.

Michelle Cox
Session: Session 4 Quick Bytes: Innovation In Diabetes Centres Using Technology
Title: OzDAFNE Pump: Optimising pumps through evidence-based group education
Time: 1610-1620
BIO:
Michelle is a Registered Nurse and Credentialed Diabetes Educator. Michelle began her nursing career working as a graduate nurse on the diabetes ward at the Royal Children’s Hospital. This sparked a life-long interest in assisting people living with diabetes. Since then, Michelle has worked in a variety of settings including cardiac nursing at RCH; rural nursing; district nursing; community health nursing; and private practice. Michelle currently works at Diabetes Victoria where part of her role is OzDAFNE facilitation and facilitator training. Michelle is the project lead for the OzDAFNE Pump project.

ABSTRACT:
This presentation will focus on introducing the OzDAFNE Pump program.

Diabetes Victoria has developed the 5 day curriculum for OzDAFNE Pump.

OzDAFNE Pump is an evidence based, structured, group education program for adults living with type 1 diabetes, using an insulin pump.

OzDAFNE Pump helps participants learn and develop the skills to improve their capacity to self-manage type 1 diabetes in a supportive group setting. The program focuses on carbohydrate counting; insulin assessment and adjustment; and managing challenging situations such as illness and exercise.

OzDAFNE Pump is well positioned to assist participants to optimise their pump therapy to fully utilise this technology.

OzDAFNE Pump will be piloted at Diabetes Victoria in Melbourne in November and will be delivered nationally by 2020.

Elizabeth Broad
Session: Session 4 Quick Bytes: Innovation In Diabetes Centres Using Technology
Title: Clinical Challenges with New Technologies – CGM and HCL
Time: 1620-1630
BIO:
Liz Broad is a Credentialed Diabetes Educator with 15 years’ experience in a variety of public and private settings including paediatric, adult and Aboriginal health services. She has a passion for Diabetes Technologies and innovative practices, especially in the paediatric setting. Since moving to Perth in 2017 she has been privileged to work with outstanding Clinical and Research teams at Princess Margaret Hospital through the transition to Perth Children’s Hospital, the only Paediatric NADC Centre of Excellence. PCH supports almost 1200 families with Diabetes across the entire State, and has a strong focus on insulin pump therapy and early intervention with CGM. The Centre was involved in clinical trials with Hybrid Closed Loop and has a significant number of families being early engagers with the technology. She manages a team of Diabetes Educators, Clinical Nurse Specialists, Enrolled Nurse, Healthy Weight Service and Endocrine Liaison Nurses.

ABSTRACT:
Advancements in Diabetes Technologies and changes in funding have provided opportunities for improved clinical outcomes and has had wide uptake in the Paediatric context of Perth Children’s Hospital. However, there have been some surprising challenges with the adoption of CGM and HCL in schools and in lived experience. This presentation will touch on some of the issues identified with increased use and earlier intervention with diabetes technologies and will focus on two particular issues of Hybrid Closed Loop technology: over-reliance on technology (CGM) and trusting the technology (HCL).

Jennifer Nicholas
Session: NADC Technology Accreditation
Title: Technology Accreditation Launch
Time: 1630-1650
ABSTRACT:
The objective of the NADC standards is to assist diabetes services to review, reflect and achieve a safe and high-quality service providing care to people using diabetes technology. The NADC technology standards for diabetes services are the only standards of its kind to offer comprehensive diabetes-specific technology standards aimed at the improvement of quality and safety.

The NADC technology standards aim to set a benchmark of service delivered by diabetes care centres across Australia.

The ADATS was offered to healthcare professionals for the first time in Australia in 2017, providing accessible diabetes advancements and technologies meeting. The event is the result of the commitment of the NADC in improving the knowledge and skill of healthcare professionals in Australia in the area of diabetes and technology.

ADATS aims to bring together prominent and influential key opinion leaders with a focus, expertise and passion for advanced technologies and therapeutics in diabetes. The full day based conference is open to registrants nationally and internationally, with advertising predominately aimed at GP’s, primary care nurses, diabetes educators, endocrinologists and diabetes health professionals who are instrumental in leading their services towards advanced diabetes management practices. The ADATS program will provide a forum of plenary session presentations, interactive demonstrations, best practice innovation, technologies and therapeutics presentations, workshops and practical sessions and provide a great base for networking opportunities.

Topics included in the program will include but are not be limited to, funding of insulin pump programs and continuous glucose monitoring clinics, use of new technologies including the latest monitoring systems and technological approaches to diabetes management, latest medications and insulins on the market and emerging therapeutics.


ADATS 2019 Sponsors